Cancer Genetics (NASDAQ:CGIX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Cancer Genetics (NASDAQ:CGIX – Get Rating) in a research note issued on Thursday. The firm set a “sell” rating on the stock.

Cancer Genetics stock opened at $1.12 on Thursday. Cancer Genetics has a fifty-two week low of $2.11 and a fifty-two week high of $17.50.

Cancer Genetics Company Profile (Get Rating)

Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.

See Also

• Get a free copy of the StockNews.com research report on Cancer Genetics (CGIX)
• MarketBeat: Week in Review 3/7 – 3/11
• Is Netflix (NASDAQ: NFLX) About To Rise From The Ashes?
• 3 Best Lumber Stocks for the Home Improvement and Home Building Boom
• The Tide May Be Turning For Stitch Fix, Inc
• MarketBeat Podcast: 2 Stocks to Buy, 1 Stock to Sell

Want More Great Investing Ideas?